RESEARCH

COSMIC and ORBIT: All patients enrolled

We are happy that a potential new treatment for OI is getting closer. Many of you have heard about the Cosmic and Orbit trials and today April 30th 2024, it’s official – all patients needed have now been enrolled.

Headshot Nick Bishop
Nick Bishop

“We would like to thank the OI community for its support, trust and participation as we complete this important step in the advancement of the setrusumab program,” said Eric Crombez, M.D., chief medical officer at Ultragenyx.

From a clinical perspective the important thing is that we are potentially closer to the goal of having a treatment for children – including very young children – with osteogenesis imperfecta,” stated Nick Bishop, Professor of Paediatric Bone Disease at University of Sheffield Medical School.

The interim Phase 2 results are very encouraging, and the speed with which we have been able to complete recruitment into both the Orbit and Cosmic studies clearly reflects the positive views of the study clinicians as a whole regarding this investigational therapy.

Read the full press release below.

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

You can find more information about (ongoing) clinical trials on OI on this webpage.

Translate »